Torrent Pharmaceuticals Ltd (TORNTPHARM) AI Stock Analysis

• Market Cap: ₹1.44T
• Dividend Yield: 0.84%
• Average Volume (3M): 7.49K
• Price to Earnings (P/E): 51.3
• Beta (1Y): 0.50
• Revenue Growth: 9.11%
• EPS Growth: 18.76%
• Country: IN
• Employees: 15,718
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 19.00
• Shares Outstanding: 338,431,850
• 10 Day Avg. Volume: 2,743
• 30 Day Avg. Volume: 7,494
• PEG Ratio: 3.66
• Price to Book (P/B): 14.19
• Price to Sales (P/S): 9.36
• P/FCF Ratio: 54.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 71.27
• Revenue Forecast (FY): ₹134.05B

• Rating: 66 Neutral
• Price Target: ₹4,613.00 ▲(28.90% Upside)
• Action: Reiterated Date: 10/17/25
• Date: Action: Reiterated 10/17/25

Torrent Pharmaceuticals demonstrates strong financial performance with significant revenue and cash flow growth. However, technical indicators suggest a lack of strong momentum, and the stock appears overvalued with a high P/E ratio. These factors contribute to a moderate overall stock score.

Positive Factors

Free Cash Flow Strength

Sustained, high free cash flow growth and strong operating-cash-to-income conversion provide durable internal funding. This supports capex, targeted M&A, R&D and debt reduction without reliance on external financing, increasing resilience to sector cyclicality.

Improved Leverage & Balance Sheet

Meaningfully lower leverage and a healthy equity ratio enhance financial flexibility over the medium term. Reduced interest burden and stronger solvency support strategic investments and buffer the business against regulatory or pricing shocks in global markets.

Robust Revenue Growth & Margins

Consistent top-line growth combined with near-50% gross margin and high ROE indicates durable operational efficiency and profitable product mix. These fundamentals support reinvestment capacity and competitive positioning across chronic therapy franchises.

Negative Factors

Modest Net Profit Margin

A mid-teens net margin constrains the company's ability to absorb persistent pricing pressure or fund large-scale growth initiatives. Over months, improving expense control and pricing power will be necessary to convert strong gross margins into higher retained earnings.

Exposure to Generics Pricing Pressure

Heavy reliance on branded generics and sales into regulated/tender markets creates structural vulnerability to price erosion and aggressive competitor moves. Sustained margin protection requires continuous portfolio differentiation and investment in brand and regulatory filings.

Room to Improve Asset Utilization

Management's own assessment of suboptimal asset utilization suggests capital is not yet fully converted into revenue. Improving turnover efficiency is necessary to lift returns organically and sustain growth without materially increasing capital deployment.

Torrent Pharmaceuticals Ltd Business Overview & Revenue Model

Company Description

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

How the Company Makes Money

Torrent Pharmaceuticals primarily makes money by selling prescription pharmaceutical formulations (finished dosage medicines) under its brands in India and in selected overseas markets. Its key revenue stream is domestic branded generics, where it earns revenue from physician-prescribed products distributed to pharmacies and hospitals via a field-force-driven marketing model and a distributor/stockist network. Internationally, it generates revenue through sales of generic formulations in regulated and semi-regulated markets, using a mix of (a) direct commercialization via its own subsidiaries/marketing infrastructure where available and (b) out-licensing, distribution, or supply arrangements with local partners in certain countries. Additional earnings can come from contract manufacturing/supply of products to partners and from royalties or milestone-type income when products are licensed out; if present, these are typically smaller than formulation sales and depend on specific agreements. Overall profitability is influenced by product mix (chronic vs. acute therapies), competitive intensity in generics, pricing and tender dynamics in certain markets, regulatory approvals for manufacturing sites and products, and the company’s ability to maintain a strong domestic prescription franchise.

Torrent Pharmaceuticals Ltd Financial Statement Overview

Summary

Torrent Pharmaceuticals shows strong financial performance with robust revenue growth and improved profit margins. The company has effectively managed cash flow and reduced leverage, though there is room for improvement in net profit margin and asset utilization.

Income Statement

Torrent Pharmaceuticals has demonstrated strong revenue growth with a 8.6% increase from 2024 to 2025. The gross profit margin is robust at approximately 49.84% for 2025. However, the net profit margin of 16.59% indicates room for improvement in controlling expenses. The EBIT margin improved significantly to 51.73%, suggesting enhanced operational efficiency.

Balance Sheet

The company maintains a stable equity ratio of 50.60%, showing a healthy balance between equity and assets. The debt-to-equity ratio improved to 0.42, reflecting a solid reduction in leverage. However, the return on equity at 25.17% suggests strong returns for shareholders, although there's potential to optimize asset utilization further.

Cash Flow

Torrent Pharmaceuticals has achieved a remarkable free cash flow growth of 42.48%, indicating effective cash management. The operating cash flow to net income ratio of 1.35 reflects strong cash generation relative to earnings. The free cash flow to net income ratio at 1.03 also underscores efficient capital expenditure control.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	121.92B	115.16B	107.28B	96.20B	85.08B	80.05B
Gross Profit	92.14B	87.40B	80.42B	68.85B	60.66B	58.58B
EBITDA	39.15B	36.76B	33.25B	28.03B	23.82B	24.29B
Net Income	21.40B	19.11B	16.56B	12.45B	7.77B	12.52B
Balance Sheet
Total Assets	155.15B	149.90B	150.61B	150.12B	131.00B	140.75B
Cash, Cash Equivalents and Short-Term Investments	10.33B	6.91B	10.04B	7.23B	5.83B	7.38B
Total Debt	28.22B	32.02B	40.22B	53.68B	40.70B	48.74B
Total Liabilities	70.66B	73.99B	82.04B	88.14B	71.47B	82.37B
Stockholders Equity	84.49B	75.91B	68.56B	61.98B	59.53B	58.37B
Cash Flow
Free Cash Flow	8.42B	19.74B	28.33B	17.94B	16.00B	16.76B
Operating Cash Flow	10.38B	25.85B	32.66B	23.68B	18.03B	20.11B
Investing Cash Flow	-2.14B	-5.40B	-1.68B	-24.15B	-1.97B	-4.49B
Financing Cash Flow	-8.26B	-22.98B	-27.80B	770.00M	-17.81B	-16.56B

Torrent Pharmaceuticals Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3578.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TORNTPHARM, the sentiment is Positive. The current price of 3578.85 is below the 20-day moving average (MA) of 4343.81, below the 50-day MA of 4143.09, and below the 200-day MA of 3699.94, indicating a neutral trend. The MACD of 40.66 indicates Positive momentum. The RSI at 50.38 is Neutral, neither overbought nor oversold. The STOCH value of 15.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TORNTPHARM.

Torrent Pharmaceuticals Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DIVISLAB	74 Outperform	₹1.62T	72.71	―	0.46%	16.43%	35.35%
LUPIN	72 Outperform	₹1.06T	20.49	―	0.57%	15.49%	64.37%
ZYDUSLIFE	72 Outperform	₹896.15B	22.07	―	1.19%	14.01%	14.62%
DRREDDY	70 Outperform	₹1.08T	21.88	―	0.63%	14.10%	9.72%
CIPLA	68 Neutral	₹1.01T	45.14	―	0.87%	6.93%	21.55%
TORNTPHARM	66 Neutral	₹1.44T	51.30	―	0.84%	9.11%	18.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Torrent Pharmaceuticals Ltd Corporate Events

Torrent Pharma Enters GLP-1 Space With First Generic Oral Semaglutide in India

Torrent Pharmaceuticals has deepened its focus on chronic disease therapies, particularly in metabolic and lifestyle-driven conditions, by leveraging its broad international footprint and strong presence in cardiovascular, gastrointestinal and central nervous system drugs. Its extensive manufacturing base and R&D investments position the company to scale complex therapies in both domestic and overseas markets.

The company has launched Semaglutide brands Sembolic and Semalix in India in both oral and injectable forms, entering the fast-growing GLP-1 receptor agonist segment for type-2 diabetes and obesity. Torrent is the first Indian firm to offer generic oral semaglutide and has priced its injectable formulation from Rs 3,999 per month, aiming to expand affordable access and strengthen its position in the competitive metabolic disorders market.

Torrent Pharma Plans Global Investor Meetings in March 2026

Torrent Pharmaceuticals Limited has announced a series of investor meetings with institutional investors across Singapore, Hong Kong and London in early March 2026, comprising both group sessions and one-on-one interactions. The roadshow-style engagement under SEBI disclosure rules underscores the company’s efforts to deepen its dialogue with global institutional shareholders and potentially broaden its international investor base, although the schedule remains subject to change based on company or investor exigencies.

Torrent Pharma to Shift Registered Office Within Ahmedabad

Torrent Pharmaceuticals Limited has approved the relocation of its registered office within Ahmedabad, shifting from its current premises at Torrent House, Off Ashram Road, to a new address at Avirat on Thaltej Shilaj Road, effective 29 January 2026. The move, cleared by the board of directors under listing regulations, represents an administrative change in the company’s corporate base within the same city and is not expected to alter its operational footprint but may reflect ongoing efforts to optimize its corporate infrastructure and governance framework.

Torrent Pharma Raises ₹11,000 Crore via Multi-series Listed NCD Issue

Torrent Pharmaceuticals Ltd has raised long-term debt capital through a private placement of senior, secured, redeemable, listed, rated non-convertible debentures (NCDs) across four series, aggregating to an issue size of INR 110 billion. The NCDs, which carry coupons ranging from 7.45% to 7.80% and tenures between two and just under five years, will be listed on the Wholesale Debt Market segment of the National Stock Exchange of India, providing the company with diversified funding and potentially enhancing its financial flexibility and balance-sheet management options for future operational and strategic needs.

Torrent Pharma Clears ₹12,500-Crore Secured NCD Issue on Private Placement

Torrent Pharmaceuticals Ltd has approved the issuance of secured, rated, listed, redeemable non-convertible debentures (NCDs) of up to ₹12,500 crore on a private placement basis, as decided by its Securities Transfer and Stakeholders Relationship Committee on 5 January 2026. The NCDs, to be listed on the Wholesale Debt Market segment of the National Stock Exchange of India, will be backed by a first-ranking exclusive charge over a designated account for issue proceeds and specified trademarks, providing a minimum security cover of 1.1 times, signalling a significant planned expansion of the company’s debt funding capacity and offering institutional investors a large secured debt instrument exposure to the company.

Torrent Pharma to Raise Up to ₹12,500 Crore via Secured NCDs on Private Placement Basis

Torrent Pharmaceuticals Limited has approved the issuance of secured, rated, listed, redeemable non-convertible debentures (NCDs) aggregating up to ₹12,500 crore through a private placement, as authorized by its Securities Transfer and Stakeholders Relationship Committee. The proposed issue, comprising up to 12,50,000 NCDs of ₹1,00,000 each, will be listed on the Wholesale Debt Market segment of the National Stock Exchange of India and secured by a first-ranking exclusive charge over the designated proceeds account and specified trademarks, providing a minimum 1.1x security cover; coupon, tenure and maturity details will be set at allotment, indicating a significant move to raise long-term debt capital that may support the company’s funding needs and balance sheet flexibility.

India Ratings Affirms Torrent Pharma at IND AA+(Stable), Assigns IND A1+ to Commercial Paper

Torrent Pharmaceuticals Limited announced that India Ratings and Research has affirmed its existing banking facilities, issuer rating and outstanding non-convertible debentures at IND AA+ with a Stable outlook, while assigning a top short-term rating of IND A1+ to its proposed commercial paper programme. The affirmation and strong short-term rating signal continued confidence in Torrent Pharma’s credit profile, support its access to bank funding and capital markets on favourable terms, and underscore the company’s solid financial position for ongoing operations and future funding needs.